Advanced Cardiology Nursing Guide

♥ HF Classification by EF

Type	EF	Characteristics
HFrEF	EF <40%	Reduced — systolic dysfunction; responds to GDMT
HFmrEF	EF 40–49%	Mildly reduced; intermediate phenotype; consider full GDMT
HFpEF	EF ≥50%	Preserved — diastolic dysfunction; treat comorbidities; SGLT2i benefit

📈 NYHA Functional Class

Class	Symptoms
I	No limitation; ordinary activity does not cause symptoms
II	Slight limitation; comfortable at rest; symptoms with moderate exertion
III	Marked limitation; comfortable at rest; symptoms with minimal exertion
IV	Symptoms at rest; cannot perform any activity without discomfort

💊 GDMT: The "Fantastic Four" for HFrEF

ACEi / ARB
or ARNI

Sacubitril-valsartan (Entresto)
↓ mortality 20%

Beta-Blocker

Carvedilol, metoprolol succinate, bisoprolol — ↓ SCD risk

MRA

Spironolactone / eplerenone — monitor K⁺ and renal function

SGLT2i

Dapagliflozin / empagliflozin — HFrEF & HFpEF benefit

ARNI Note: Sacubitril-valsartan must NOT be started within 36 hours of an ACEi (risk of angioedema). Titrate every 2 weeks targeting sacubitril 97mg / valsartan 103mg twice daily.

⚠ Decompensated HF Triggers — FAILURE Acronym

FAILURE
F	Forgot medications (non-adherence — very common in GCC)
A	Arrhythmia / Anaemia (new AF most common precipitant)
I	Ischaemia / Infarction (ACS causing acute decompensation)
L	Lifestyle / dietary indiscretion (high-sodium meals, excess fluids)
U	Upregulation of renin-angiotensin (renal failure, NSAIDs, contrast)
R	Respiratory infection (pneumonia, COVID-19)
E	Embolism (pulmonary embolism causing acute right HF)

📊 Forrester Haemodynamic Profiles

Based on congestion (wet/dry) and perfusion (warm/cold). Assessed clinically.

📅 Fluid Restriction & Daily Weight

Fluid restrict to 1.5–2 L/day in decompensated HF
Weigh daily at same time, after voiding, before eating, in same clothing
Alert criteria: Weight gain >1 kg overnight or >2 kg in 3 days → call HF team
Document and trend weight — provide patient with weight diary
Sodium restriction <2 g/day in symptomatic HF (avoid processed foods, fast food)
Monitor input/output; target net negative balance in decompensation

📋 BNP / NT-proBNP Interpretation

Marker	Rule-Out HF	Confirms HF
BNP	<100 pg/mL	>400 pg/mL
NT-proBNP	<125 pg/mL (<75 yr) <300 pg/mL (≥75 yr)	>900 pg/mL (<75 yr)

Caution: BNP may be falsely LOW in obese patients and those with HFpEF. AF, PE, and renal failure can raise BNP without HF.

🧮 HF 1-Year Mortality Risk Estimator

Educational tool based on validated prognostic variables. Not a substitute for clinical judgement.

NYHA Class BNP Level (pg/mL)

Sodium (Na⁺) mmol/L eGFR (mL/min/1.73m²)

—

Estimated 1-Year Mortality

⚡ Atrial Fibrillation Management

Rate vs Rhythm Control

Strategy	Goal	Agents
Rate Control	Resting HR <80 bpm (lenient <110 bpm if asymptomatic)	Beta-blockers, CCBs (diltiazem, verapamil), digoxin
Rhythm Control	Restore & maintain sinus rhythm	Flecainide (no structural disease), amiodarone, sotalol; catheter ablation

CHA₂DS₂-VASc — Anticoagulation

Score ≥2 (men) / ≥3 (women): OAC recommended. Score 1 (men) / 2 (women): consider OAC. DOACs preferred over warfarin in non-valvular AF.

📸 Cardioversion Nursing

Confirm AF >48h or unknown duration: obtain TOE to exclude LA thrombus OR anticoagulate for ≥3 weeks before cardioversion
Ensure therapeutic anticoagulation (INR 2–3 or DOAC dose); continue ≥4 weeks post-cardioversion
NPO ≥4h (conscious sedation); obtain IV access, O₂, suction, defib pads
Titrate propofol / midazolam + fentanyl per anaesthesia protocol; continuous SpO₂, ETCO₂
Synchronised DC shock: 120–200 J biphasic (start lower); place pads anterior-posterior for best efficacy
Document rhythm and patient response; monitor ECG minimum 30 min post-procedure
Ensure discharge instructions re anticoagulation and follow-up

☍ SVT Management

Vagal Manoeuvres (First Line)

Modified Valsalva: Strain supine 15 sec → passive leg raise 45° for 15 sec (REVERT trial: 43% vs 17% conversion) — preferred technique
Carotid sinus massage: unilateral only, avoid if carotid bruit present
Ice-water facial immersion (especially paediatric)

Adenosine Protocol

Adenosine 6mg rapid IV (antecubital or central) flush immediately with 20 mL NS. If no conversion after 1–2 min → 12 mg. Warn patient: transient chest tightness, flushing, near-syncope (half-life <10 sec). Monitor ECG continuously. Contraindicated in asthma — use verapamil instead.

⚠ VT vs SVT with Aberrancy — Brugada Algorithm

Absence of RS complex in all precordial leads? → VT
RS interval >100 ms in any precordial lead? → VT
AV dissociation present? → VT
Morphology criteria: LBBB with R in V1 >30 ms, or RBBB with QR in V1? → VT
None of above: → SVT with aberrancy

Clinical rule: When in doubt, treat as VT. Do NOT give verapamil for broad-complex tachycardia of uncertain origin — risk of haemodynamic collapse in true VT.

🔋 Complete Heart Block — Pacing

Transcutaneous Pacing (TCP) — Emergency

Attach defibrillator pads (anterior-posterior preferred); ensure good skin contact — shave if necessary
Set rate: 70–80 bpm (or 10 bpm above intrinsic rate)
Increase mA until capture: start 40 mA → increase until pacing spike followed by QRS + palpable pulse (usually 60–90 mA)
Analgesia/sedation: morphine + midazolam — pacing is painful
Document capture threshold; verify BP and pulse with each delivered spike
Arrange urgent transvenous pacing if prolonged pacing needed

Transvenous Pacing — Nursing Care

Assist with venous access (subclavian or femoral preferred for temporary)
Maintain patient flat (femoral) or minimal movement (subclavian)
Check daily: rate, output (mA), sensitivity; document threshold tests
Monitor for lead displacement: loss of capture, patient lightheadedness
Change dressings with aseptic technique; assess for infection
Educate: do not pull or tug at catheter; call if dizzy/palpitations
Arrange electrophysiology review for permanent pacemaker implantation

🔭 Electrophysiology Study (EPS) — Nursing

Pre-Procedure

NPO ≥6h (solids); clear liquids until 2h pre-procedure
Consent: explain catheters introduced via femoral/subclavian veins, risk of cardiac perforation, bleeding, arrhythmia induction
Hold antiarrhythmic drugs for ≥5 half-lives (as per EP team)
IV access bilateral; baseline 12-lead ECG; mark pulses bilaterally
Clip/shave bilateral groins; antiseptic wash

Post-Procedure

Femoral access: 4–6h flat bed rest; manual pressure or closure device
Vital signs every 15 min × 4, then 30 min × 2, then hourly
Check access sites for haematoma, ooze; mark haematoma borders
Check distal pulses and limb perfusion bilaterally
Monitor ECG: new rhythm post-ablation expected; reassure patient
Hydrate post-procedure (contrast + fasting); monitor urine output
Mobilise gradually; discharge criteria: haemostasis, stable vitals, voided

🧮 CHA₂DS₂-VASc Score Calculator

For non-valvular AF. Per 2023 ESC AF Guidelines. Each criterion checked = points as shown.

C — Congestive Heart Failure (or EF <40%)

H — Hypertension (BP >140/90 or on treatment)

A₂ — Age ≥75 years

D — Diabetes Mellitus

S₂ — Stroke / TIA / Thromboembolism (prior)

V — Vascular Disease (MI, PAD, aortic plaque)

A — Age 65–74 years

Sc — Female Sex (stroke risk modifier)

CHA₂DS₂-VASc Score

Check criteria above to see anticoagulation recommendation.

💌 Dilated Cardiomyopathy (DCM)

Causes

Peripartum Cardiomyopathy (PPCM) — GCC Focus

Onset: last month of pregnancy to 5 months postpartum
Risk factors: multiparity, older maternal age, twin pregnancy, hypertension — all common in GCC
Bromocriptine: 2.5 mg BD for 2 weeks → 2.5 mg OD for 6 weeks; blocks prolactin (promotes recovery); caution: thromboembolism risk — ensure anticoagulation
Management: standard HFrEF therapy; avoid ACEi/ARB while breastfeeding; beta-blockers safe
EF often recovers partially or fully; re-evaluate at 6 months
Advise against subsequent pregnancy if EF does not recover

▪ Hypertrophic Cardiomyopathy (HCM)

Key Pathophysiology

LVOTO: Dynamic obstruction — worsened by hypovolaemia, tachycardia, Valsalva, standing
Valsalva murmur: Systolic ejection murmur increases with Valsalva (↓ preload → ↑ obstruction); squatting decreases murmur
SAM (systolic anterior motion of mitral valve) contributes to MR and obstruction

Sudden Death Risk & ICD

HCM Risk-SCD calculator (ESC): Score ≥6%/5yr → ICD implantation recommended. Risk factors: max wall thickness ≥30 mm, family history SCD, unexplained syncope, NSVT, LVOTO ≥30 mmHg, LA diameter.

Septal Reduction Therapy

Procedure	Method	Nursing Care
Surgical Myectomy	Resection of basal septum via open-heart surgery	Standard cardiac surgery post-op; monitor for AV block (need PPM)
Alcohol Septal Ablation	Ethanol injection into septal perforator branch	Post-cath monitoring; very high rate of complete heart block — temporary pacing wire in situ; PPM often needed

🔗 Restrictive Cardiomyopathy — Cardiac Amyloid

Recognition

"Sparkling" appearance on echo (granular myocardium)
Low voltage on ECG despite thick walls — classic mismatch
HFpEF unresponsive to usual measures; peripheral neuropathy, CTS
ATTRv (hereditary) and ATTRwt (wild-type, elderly men)

Technetium Scan (99mTc-DPD/PYP)

Grade 2–3 uptake confirms ATTR amyloid (sensitivity/specificity ~99%)
Must exclude AL amyloid first (serum FLC, SPEP) — Tc scan less reliable in AL
Nursing: explain nuclear medicine scan; no special prep needed for 99mTc-DPD beyond IV access

Tafamidis

Tafamidis 61 mg OD — TTR stabiliser; reduces mortality and hospitalisation (ATTR-ACT trial). Available in GCC; confirm insurance coverage and ensure patient counselled on long-term adherence.

⚡ Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Task Force Criteria (2010)

Category	Major	Minor
Structural	RV dilation/dysfunction on echo/MRI/angiography	Milder RV dilation/dysfunction
Tissue characterisation	Fibrofatty replacement on biopsy	—
Repolarisation	T-wave inversion V1–V3	T-wave inversion V1–V2 (LBBB)
Depolarisation	Epsilon wave; terminal activation duration >55 ms	Late potentials (SAECG)
Arrhythmia	LBBB-type VT (sustained/non-sustained)	>500 PVCs/24h
Family Hx/Genetics	ARVC in 1st-degree relative confirmed; pathogenic mutation	ARVC in 1st-degree relative; SCD <35 yr in 1st-degree relative

Athlete's Heart Differential

Differentiating ARVC from athlete's heart is critical. ARVC: epsilon waves, LBBB VT, positive family history, RV systolic dysfunction, fibrofatty replacement. Athlete's heart: symmetric remodelling, normal systolic function, resolves with deconditioning.

Management: ICD for high-risk ARVC; restrict competitive sports; sotalol/amiodarone for arrhythmia burden; genetic screening of 1st-degree relatives.

⚒ Permanent Pacemaker (PPM) Nursing

Post-Implant Arm Restriction

Dominant side implant (left subclavian typical): Restrict arm above shoulder level for 4–6 weeks to allow lead fixation and prevent lead displacement. No overhead reaching, swimming, heavy lifting (>2 kg), or vigorous arm movements.

Wound Care

Keep wound dry for 48h; no showering until dressing removed (usually 24–48h)
Monitor for haematoma (firm swelling normal early; fluctuant = concerning)
Report: fever, wound redness, increasing pain, discharge — signs of pocket infection
Avoid tight clothing over device site

Device Check & Programmer

Interrogation at 6 weeks post-implant, then 6–12 monthly
Threshold testing: ensure pacing threshold <1.0 V (adequate safety margin)
Sensing threshold: confirm adequate R/P wave amplitude
Battery longevity check: alert when ERI (Elective Replacement Indicator) reached

Magnet Application

Applying magnet over PPM → asynchronous pacing at fixed rate (typically 85–100 bpm). Used to override inhibition in pacemaker-dependent patients undergoing surgery (cautery interference). Remove magnet to restore demand pacing.

⚡ Implantable Cardioverter-Defibrillator (ICD)

Patient & Family Education

Shock therapy anxiety: Patients and family often fear the device. Explain that shocks are brief but uncomfortable. Provide panic management strategies. Refer to cardiac psychology if distress significant — common in GCC families who are closely involved in patient care.

Driving Restrictions — GCC

Private driving: Refrain for 6 months after appropriate shock (sustained VT/VF). 4 weeks for prophylactic ICD implantation without prior arrhythmia event. Professional/commercial driving: may be permanently restricted — advise patient to inform driving authority (relevant in GCC context: Gulf countries require physician declaration).

Remote Monitoring

Transmit daily automatic checks to clinic via Bluetooth/mobile app (Merlin@home, Carelink, Latitude)
Nurse reviews alerts: new VT/VF episodes, battery status, lead impedance change
Educate patient: keep transmitter plugged in, within range of device during sleep

Magnet over ICD

Suspends tachyarrhythmia detection and shock therapy (does not affect pacing). Used when: patient receiving inappropriate shocks, end-of-life care, or surgical environment. Remove magnet to re-enable therapy.

🔌 Cardiac Resynchronisation Therapy (CRT)

Indications

LBBB with QRS ≥150 ms + EF ≤35% + NYHA II–III on optimal GDMT
Three leads: RA, RV, LV (via coronary sinus → posterolateral branch)
CRT-D (ICD function) preferred in patients with SCD risk
CRT-P (pacing only) in elderly or those who decline ICD

Biventricular Pacing & Optimisation

Target: >98% biventricular pacing — check at every device interrogation
AV delay optimisation: typically via echocardiographic Doppler (mitral inflow) or device-based algorithm
VV interval optimisation: LV lead timed relative to RV for maximum synchrony
Non-responders (~30%): check lead position, pacing percentage, optimisation; consider LV lead repositioning

Nursing note: CRT benefits may take 3–6 months to manifest. Patients should be reassured and adherence to GDMT maintained throughout.

📋 Device Terminology Reference

Term	Meaning
DDD	Dual-chamber sensing and pacing; tracks atrial rate
VVI	Ventricle sensed, paced, inhibited — single chamber
AOO / VOO	Asynchronous pacing (magnet mode)
ERI	Elective Replacement Indicator — battery nearing end
EOL	End of Life — device must be replaced urgently
Threshold	Minimum energy to capture myocardium reliably
Impedance	Lead resistance (high = lead fracture; low = insulation break)
Sensing	Device ability to detect intrinsic cardiac signals
Oversensing	Device detects non-cardiac signals → inhibits pacing
Undersensing	Fails to detect intrinsic beats → delivers unnecessary spikes

📻 Echocardiography Nursing

TTE (Transthoracic Echo)

Patient positioning: Left lateral decubitus for standard views; supine for subcostal; sitting forward for aortic views
Apply gel liberally; probe sites: parasternal (left sternal border, 2nd–4th ICS), apical (apex impulse), subcostal (below xiphoid), suprasternal (jugular notch)
Dim lights; patient removes top clothing; provide drape for privacy
No special preparation; may eat/drink normally
Document: EF, wall motion, valves, pericardial effusion, RV function

TOE (Transoesophageal Echo)

NPO ≥6h (solids); clear liquids until 2h
Obtain written consent; explain probe passage via mouth into oesophagus
IV access; topical throat spray (lignocaine); bite guard in situ
Conscious sedation: midazolam 1–2 mg IV ± fentanyl; monitor SpO₂, BP, ECG
Position: left lateral; suction available; supplemental O₂ via nasal cannula
Post-procedure: NPO 1h until gag reflex returns; monitor for laryngospasm
Oesophageal perforation: rare but serious — report dysphagia, chest pain post-TOE

🏃 Stress Testing

Exercise Tolerance Test (ETT) — Bruce Protocol

Stage	Speed (mph)	Grade (%)	Duration
1	1.7	10	3 min
2	2.5	12	3 min
3	3.4	14	3 min
4	4.2	16	3 min

Absolute Contraindications

Stop Criteria

ST depression >2 mm or elevation; severe angina
SBP drop >10 mmHg with increasing workload
Sustained VT or significant arrhythmia
Patient request, severe dyspnoea, dizziness
Target HR achieved (85% maximum predicted: 220 - age)

Recovery Monitoring

Monitor ECG and BP every 2 min for minimum 6–8 min post-exercise or until HR <100 bpm and no symptoms. Emergency trolley at bedside throughout.

Pharmacological Stress Testing

Adenosine/Regadenoson (MPS)

Vasodilator: causes coronary hyperaemia — ischaemic areas show reduced uptake
Bronchospasm risk — absolute contraindication: asthma/COPD/active wheeze; have aminophylline (reversal agent) available
Side effects: flushing, dyspnoea, chest tightness, AV block (brief)
Withhold caffeine ≥24h; hold xanthines 24–48h prior
Aminophylline 50–100 mg IV reverses adenosine effects

Dobutamine Stress Echo (DSE)

Infusion: 5 → 10 → 20 → 30 → 40 mcg/kg/min (3 min stages)
Target: 85% max HR; atropine 0.25–0.5 mg IV if inadequate response
Monitor continuously: ECG, BP, echo wall motion
Stop for: new RWMA, VT, severe hypertension (>220/120), ST changes, intolerable symptoms
Contraindicated: significant tachyarrhythmia, uncontrolled hypertension, severe HF, recent MI

🔭 Cardiac Catheterisation Lab Nursing

Pre-Procedure

NPO ≥6h (solids); IV fluids if prolonged fasting
Obtain written informed consent — risks: bleeding, contrast reaction, AKI, stroke, MI, death
Hold metformin on day of procedure and 48h post (AKI risk with contrast) — ensure patient/ward aware
Hold antiplatelets only if instructed by operator (primary PCI: do NOT hold)
Baseline renal function, FBC, coagulation; type & screen
Document allergies; pre-medicate if contrast allergy history (steroids + antihistamine)
Bilateral groin clip/shave; mark distal pulses; radial access prep if planned
IV access × 2; bilateral BP baseline documentation

Post-Procedure

Receive patient from cath lab with handover: access site, sheath size, heparin reversal, anticoagulation plan
Femoral: bed rest ≥2–4h after sheath removal; radial: compression band (TR Band) — deflate per protocol (usually 2h)
Vitals and access site check every 15 min × 4, every 30 min × 2, hourly × 4
Assess: haematoma, ooze, haemodynamic stability; mark and date any haematoma
Check distal pulses bilaterally; pallor/pain/paraesthesia → urgent assessment
Sheath removal: confirm ACT <150–180 s or per protocol; firm manual pressure ≥15–20 min; confirm haemostasis before releasing
Hydration post-contrast: at least 500 mL–1 L IV NS over 4–6h unless HF
Discharge: instruct no driving 24h, avoid heavy lifting 3–5 days, return if groin swelling/pain

🌍 Cardiovascular Epidemiology in the GCC

Young MI: CAD presenting in men in their 40s and 50s is disproportionately prevalent in GCC — driven by high rates of DM, hypertension, obesity, and smoking (especially shisha/waterpipe)
Hypertensive Heart Disease: High burden; HTN rates estimated 25–40% across GCC; significant proportion undiagnosed or uncontrolled
Familial Hypercholesterolaemia (FH): Highly underdiagnosed; founder effect in some GCC populations. GCC SCORE may underestimate risk. Dutch Lipid Clinic Network criteria recommended for diagnosis.
Type 2 DM: GCC has one of the world's highest T2DM prevalences (UAE >17%, Kuwait >20%) — directly driving CAD and HF burden
Cardiac Rehab: Very low uptake (estimated <15%) — barriers include: cultural modesty (mixed-gender settings), limited programmes, transport, return to work pressure

🏠 Leading Cardiac Centres in GCC

Centre	Country	Specialty Notes
Cleveland Clinic Abu Dhabi	UAE	Full cardiac surgery, TAVI, complex EP, LVAD
King Faisal Heart Institute	KSA (Riyadh)	Pioneer cardiac surgery centre in KSA; transplantation programme
HMC Cardiology — Heart Hospital	Qatar (Doha)	National cardiac centre; high PCI volume; EP programme
Rashid Hospital Cardiac	UAE (Dubai)	High primary PCI volume; GCC hub for trauma cardiology
King Abdulaziz Cardiac Centre	KSA (Riyadh)	Major public cardiac centre; congenital heart disease

⚒ TAVI/TAVR in the GCC

TAVR volumes growing rapidly — driven by ageing population and increased indication (intermediate/low-risk aortic stenosis)
GCC centres performing TAVR: Cleveland Clinic Abu Dhabi, King Faisal Heart Institute, HMC Doha, KFSH&RC
Nursing Role: Pre-TAVR: frailty assessment, baseline 6MWT, echocardiography coordination, consent facilitation; Post-TAVR: vascular access monitoring (large-bore femoral), new LBBB/heart block watch (PPM implant rate ~10–15%), ambulation day 1
Heart team discussion mandatory — cardiac surgery, interventional cardiology, anaesthesia, nursing specialist, imaging

⚡ Wolff-Parkinson-White (WPW) in GCC

Anecdotally higher prevalence of WPW reported in young Saudi Arabian males. Exact data limited; possible genetic/consanguinity component.

Clinical Considerations

ECG features: delta wave, short PR interval (<120 ms), widened QRS
Risk stratification: asymptomatic WPW — exercise test & EP study to assess accessory pathway refractory period
Dangerous: AF in WPW → rapid conduction down accessory pathway → VF; DO NOT give adenosine, digoxin, or verapamil (block AV node, increase bypass conduction)
Treatment: RF catheter ablation — curative (>95% success); recommend ablation for all symptomatic patients and high-risk asymptomatic individuals
Screening of first-degree relatives; avoid competitive sports until risk stratification complete

🎓 Cardiac Nursing Specialist Pathway in GCC

Current State

No unified GCC-wide cardiac nursing specialty certification exists as of 2025
Most experienced cardiac nurses hold international credentials: CCRN (AACN), RCIS (cardiovascular invasive specialist — USA), British Cardiac Society courses
Saudi Commission for Health Specialties (SCFHS) developing nursing specialisation tracks; cardiac care under critical care umbrella
UAE: DOH/DHA recognise specialty nurses; cardiac nursing under critical care classification

Recommended Development Path

Foundation: 2+ years cardiac ward/CCU experience
Core certifications: ACLS (mandatory), BLS instructor (valuable), 12-lead ECG interpretation course
Advanced: CCRN (USA), European Cardiac Nurse Certification (if pursuing European recognition)
Subspecialty: Cath lab (RCIS), EP lab, echocardiography assistant (ASE courses), HF nursing specialist
Postgraduate: MSc Cardiac Nursing (UK/AUS universities with distance learning — accessible from GCC)
Local CME: annual congresses — GCCSA (Gulf Cardiology), Saudi Heart Association, Emirates Cardiac Society

Cultural Competence: GCC cardiac nurses must be skilled in family-centred communication, supporting end-of-life conversations within Islamic framework, facilitating male/female patient preferences in care delivery, and multilingual patient education (Arabic, Urdu/Hindi for expat populations).